Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 3 7Phase 1/2 4Phase 1 3Phase 2/3 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Hematologic Neoplasms 2Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cytarabine 184Cyclophosphamide 176fludarabine 146Azacitidine 121venetoclax 115fludarabine phosphate 104Rituximab 80Decitabine 74Filgrastim 58Specimen Handling 55Etoposide 55Lenalidomide 47Biopsy 45Dexamethasone 41Methotrexate 40Bortezomib 40Mitoxantrone 39Granulocyte Colony-Stimulating Factor 39Daunorubicin 39Vincristine 37Melphalan 36ibrutinib 35Tacrolimus 35Dasatinib 34Whole-Body Irradiation 32Clofarabine 32Peripheral Blood Stem Cell Transplantation 31Mycophenolic Acid 31Injections 31Idarubicin 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Homoharringtonine × Other hematologic neoplasm × Clear all
NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT02141477 2018-02-13

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 1 Terminated
2 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT01844869 2015-01-30

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡